Effects of Drugs on Exercise Tolerance in Patients with Cardiovascular Disease

  • Martin Stauch


A consequence of most cardiovascular diseases is exercise limitation. The main causes of exercise intolerance are angina pectoris due to myocardial ischemia, dyspnea in congestive heart failure due to loss of muscle mass, and muscular dysfunction or valvular disease. Besides the heart, peripheral arterial occlusive disease is a major cause for exercise intolerance. Possibilities for drug therapy are limited in this disease.


Congestive Heart Failure Angina Pectoris Exercise Tolerance Loop Diuretic Peripheral Arterial Occlusive Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abrams J. Nitrate tolerance and dependence. Am. Heart J. 99: 113–123, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Badger F., G. Brown, C.A. Gallery, E.L Bolson, and H.T. Dodge. Coronary artery dilatation and hemody-namic responses after isosorbide dinitrate therapy in patients with coronary artery disease. Am. J. Cardiol. 56:390–395, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Bassenge E., and A. Mulsch. Anti-ischemic actions of molsidomine by venous and large coronary dilatation on combination with antiplatelet effects. J. Cardiovasc. Pharmacol. 14:23–28, 1989.Google Scholar
  4. 4.
    Brown B.G., E.L. Bolson, R.B. Peterson, CD. Pierce, and H.T. Dodge. The mechanisms of nitroglycerin action: Stenosis vasodilation as a major component of drug response. Circulation 65: 1089–1097, 1981.CrossRefGoogle Scholar
  5. 5.
    Brown B.G. Response of normal and diseased epicardial coronary arteries to vasoactive drugs: Quantitative angiographic studies. Am. J. Cardiol. 56: 23E–29E, 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    Brown E.J., P.H. Chew, A. MacLean, K. Gelperin, J.P. Ilgenfritz, and M. Blumenthal. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Amer.J.Cardiol. 75: 596–600, 1995.PubMedCrossRefGoogle Scholar
  7. 7.
    Bussmann W.-D., and K. Wienhöfer. Akut-und Langzeiteffekte von 100 mg N-Methyldopamin (Ibopamin) bei Patienten mit chronischer Herzinsuffizienz Stadium II-III NYHA. Herz/Kreislauf 27:135–138, 1995.Google Scholar
  8. 8.
    Lieverse A.G., DJ. vanVeldhuisen, A.J. Smit, J.G. Zijlstra, S. Maeijer, W.D. Reitsma, K.I. Lie, and A.R.J. Girbes. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. J. Cardiovasc.Pharmacol. 25:361–367, 1995.PubMedCrossRefGoogle Scholar
  9. 9.
    Littler W.A., and D.J. Sheridan. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Brit.Heart J. 73:428–433, 1995.PubMedCrossRefGoogle Scholar
  10. 10.
    Macgowan G.A., D. O’Callaghan, H. Webb, and J.H. Horgan. The effects of captopril on training in patients with ischemic heart disease. Clin. Cardiol. 15:330–334, 1992.PubMedCrossRefGoogle Scholar
  11. 11.
    McLenachan J.M., J.T. Wilson, and H.J. Dargie. Importance of acillary properties of beta-blockers in angina: A study of celiprolol and atenolol. Br. Heart J. 59:685–689, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Nechwatal W., M. Stauch, H. Sigel, P. Kress, F. Bitter, H. Geffers, and W.E. Actam. Effects of Molsidomine on global and regional left ventricular function at rest and during exercise in patients with angina pectoris. Clin. Cardiol. 4: 248–253, 1981.PubMedGoogle Scholar
  13. 13.
    Nechwatal W., E. König, J. Isbary, H. Greding, and M. Stauch. Haemodynamic and electrocardiographic effects of frusemide during supine exercise in patients with angina pectoris. Br. Heart J. 44: 67–74, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Nechwatal W., A. Stange, H. Sigel, P. Kress, A. Resch, and M. Stauch. Der Einfluß von Piretanid auf die zentrale Hämodynamik und Belastungstoleranz von Patienten mit Angina pectoris. Herz/Kreisl. 14: 91–96, 1982.Google Scholar
  15. 15.
    Needleman P., S. Lang, and E.M. Johnson. Organic nitrates: Relationship between biotransformation and rational angina pectoris therapy. J. Pharmacol. Exp. Ther. 181: 489–497, 1972.PubMedGoogle Scholar
  16. 16.
    Olsen S.L., E.M. Gilbert, D.G. Renlund, D.O. Taylor, F.D. Yanowitz, and M.R. Bristow. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. JACC 25:1225–31, 1995.PubMedGoogle Scholar
  17. 17.
    Parker J.O., B. Farrell, K.A. Lahey, and J. Moe. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 316:1440–1444, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Panvilov V., I. Wahlqvist, and G. Osson. Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc. Drugs Therap. 9:273–287, 1995.CrossRefGoogle Scholar
  19. 19.
    Pouleur, H. Neurohormonal and hemodynamic effects of ibopamine. Clin. Cardiol. 18:1-17-1-21, 1995.Google Scholar
  20. 20.
    Stauch M, Grewe N, and Nissen H. Die Wirkung von 2-und 5-Isosorbidmononitrat auf das Belastungs-EKG von Patienten mit Koronarinsuffizienz. Verh. Dtsch. Ges. Kreislaufforsch. 41, 182–184, 1975PubMedGoogle Scholar
  21. 21.
    Stauch M, and N. Grewe. Die Wirkung von Isosorbiddinitrat, Isosorbid-2-und 5-Mononitrat auf das Belastungs-EKG und auf die Hämodynamik während Vorhofstimulation bei Patienten mit Angina pectoris. Z Kardiol. 68:687, 1979.PubMedGoogle Scholar
  22. 22.
    Stauch, M., G. Grossmann, A. Schmidt, P. Richter, J. Waitzinger, D. Wanjura, W.E. Actam, and W. König. Effect of gallopamil on left ventricular function in regions with and without ischaemia. Europ. Heart J. 8 (Suppl.G) 77-83, 1989.Google Scholar
  23. 23.
    Thadani U., S.F. Hamilton, E. Olson, J.L. Anderson, R. Prasad, W. Voyles, R. Doyle, E. Kirsten, and M. Teague. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am. J. Cardiol. 59, 756–762, 1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Thadani U., and P.J. de Vane. Efficacy of isosorbide mononitrate in angina pectoris. Amer. J. Cardiol. 70:67G–71G, 1992.PubMedCrossRefGoogle Scholar
  25. 25.
    Tzivioni, D., S. Gottlieb, N.S. Khurmi, A. Medina, A. Gavish, and S. Stern. Effect of Benazepril on myocardial ischemia in patients with chronic stable angina pectoris. Eur. Heart J. 13:1129–1134, 1992.Google Scholar
  26. 26.
    Unger P., A. Leone, M Staroukine, S. Degre, and G. Berkenboom. Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate. J. Cardiovasc. Pharmacol 18:888–894, 1991.PubMedCrossRefGoogle Scholar
  27. 27.
    Winter U.J., M. Böhm, and E. Erdmann. Überlegungen zum möglichen Stellenwert der neuen Ca2-An-tagonisten bei der Herzinsuffizienztherapie. Herz/Kreislauf 27:162–167.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Martin Stauch
    • 1
  1. 1.Abteilung Sport- und Leistungsmedizin University of UlmUlmGermany

Personalised recommendations